<?xml version="1.0" encoding="UTF-8"?>
<p id="p0040">SARS-CoV-2 is a human coronavirus causing the COVID-19 disease. It emerged in China in December 2019 and rapidly propagated in numerous countries, having contaminated more than one million people and killing more than 55,000 up to April 3, 2020. Antiviral treatments are warranted to contain the epidemics. Several candidates are already being investigated, including type 1 interferon (IFNâ€“I) (
 <xref rid="bib24" ref-type="bibr">Martinez, 2020</xref>; 
 <xref rid="bib5" ref-type="bibr">Belhadi et al., 2020</xref>). Indeed, in the context of emerging viral infections, IFN-I are often evaluated (usually in combination with other drugs) before specific treatments are developed, due to their unspecific antiviral effects (
 <xref rid="bib13" ref-type="bibr">Gao et al., 2010</xref>; 
 <xref rid="bib21" ref-type="bibr">Loutfy et al., 2003</xref>; 
 <xref rid="bib27" ref-type="bibr">Omrani et al., 2014</xref>). We aimed to review the evidence supporting the evaluation of IFN-1 in the treatment of coronaviruses and to discuss its potential in SARS-CoV-2.
</p>
